These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1988574)

  • 1. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
    Kleinerman ES; Snyder JS; Jaffe N
    J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
    MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
    J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
    Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
    Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F; MacEwen EG; Kurzman ID
    Cancer Res; 1993 Sep; 53(17):3986-91. PubMed ID: 8358727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W; Griffin JR; Kleinerman ES
    Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
    Mori K; Ando K; Heymann D
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
    Anderson P
    Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
    Fidler IJ; Fogler WE; Brownbill AF; Schumann G
    J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [L-MTP-PE--a potential antineoplastic agent].
    Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
    Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.